Drug or technology
2 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
Latest
Everything in the corpus, newest first.
AUG 7, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval action for a labeling change to fosaprepitant dimeglumine; does not contain clinical trial efficacy or safety data.
JUN 10, 2026 · REGULATORY LABEL UPDATE
U.S. Food and Drug Administration
FDA supplemental approval for fosaprepitant labeling; this is a regulatory action, not a clinical evidence record, and does not report trial outcomes or efficacy data.